Mainz Biomed NV ( NASDAQ:MYNZ ) , the molecular genetics diagnostic company making a non-invasive blood-based screening test for early detection of pancreatic cancer, reported results from a feasibility study that could have widespread implications for the early detection of cancer.

MYNZ

<p>Mainz Biomed NV（納斯達克代碼：MYNZ），一家開發非侵入性血液篩查測試以早期檢測胰腺癌的分子遺傳診斷公司，報告了一項可行性研究的結果，該研究可能對癌症的早期檢測產生廣泛影響</p>

Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland

Mainz Biomed 更新：胰腺癌早期檢測測試顯示出前所未有的結果，公司準備在瑞士推出 ColoAlert